The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. - Charbonnel,B.; Dormandy,J.; Erdmann,E.; Massi-Benedetti,M.; Skene,A. (Diabetes Care, 2004)